Company news

Guardant Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

December 8, 2025

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

December 4, 2025

Rafay Systems Helps Shape Guardant Health–Led Consortium Defining Open Standard for AI-Ready Data Access

November 12, 2025

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

November 11, 2025

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

November 9, 2025

New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response

November 5, 2025

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 5, 2025

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

November 4, 2025

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

November 4, 2025

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

November 4, 2025

Guardant Health Announces Proposed Public Offering of Common Stock

November 3, 2025

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

November 3, 2025

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

October 28, 2025

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

October 26, 2025

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

October 25, 2025

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

October 14, 2025

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

October 8, 2025

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

September 28, 2025

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States

September 23, 2025

Alex M. Azar II Joins Guardant Health Board of Directors

September 14, 2025

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

September 10, 2025

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

September 7, 2025

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

September 3, 2025

Guardant Health to Host Investor Day on September 24, 2025

August 27, 2025

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 25, 2025

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

August 3, 2025

Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

July 29, 2025

Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+

July 29, 2025

New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer

July 28, 2025

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

July 14, 2025

Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

July 13, 2025

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

June 9, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

June 8, 2025

FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test

June 2, 2025

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

June 2, 2025

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

June 1, 2025

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

May 30, 2025

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

May 26, 2025

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

May 21, 2025

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

May 20, 2025

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

May 19, 2025

TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

May 7, 2025

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

April 29, 2025

Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types

April 28, 2025

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

April 27, 2025

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

April 23, 2025

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

April 21, 2025

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

April 9, 2025

Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada

April 2, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.